Clinical Trials Logo

Cognitive Dysfunction clinical trials

View clinical trials related to Cognitive Dysfunction.

Filter by:

NCT ID: NCT00611897 Completed - Clinical trials for Cognitive Dysfunction

N-acetylcysteine and NMDA Antagonist Interactions

Start date: January 2006
Phase: Phase 1/Phase 2
Study type: Interventional

This study tests the hypothesis that extrasynaptic mechanisms are critically linked with cognitive effects of NMDA antagonism as evidenced by event-related potentials (ERPs) in healthy humans.

NCT ID: NCT00611572 Completed - Clinical trials for Cognitive Dysfunction

GABA-glutamate Interactions and Psychosis

Start date: January 2007
Phase: Phase 1
Study type: Interventional

This study investigates the interactions between NMDA (N-Methyl-D-aspartic acid) antagonism and GABA (gamma-aminobutyric acid) system as it relates to cognitive function assessed by ERPs (event-related potentials) in healthy volunteers.

NCT ID: NCT00597545 Terminated - Diabetes Clinical Trials

Effect of Raised CBF During CEA on Cognition in DM Patients

Start date: March 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if we can reduce the incidence of cognitive dysfunction — difficulty in performing certain pencil-paper, memory, finger dexterity and thinking type of tasks called neuropsychometric tests — in patients with adult onset diabetes mellitus (DM) undergoing surgery on the carotid artery (CEA). We hypothesize that cognitive dysfunction can be decreased in patients with type II DM by augmenting cerebral blood flow with a shunt during carotid endarterectomy compared to patients with Type II DM who are treated with "conventional" management in which a shunt is placed only if the electroencephalogram (EEG) indicates cerebral ischemia.

NCT ID: NCT00594633 Completed - Brain Tumor Clinical Trials

Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors

Start date: October 2004
Phase: Phase 1
Study type: Interventional

A significant number of brain tumor patients who received radiation or chemotherapy have thinking problems as a result of their treatment. The purpose of this study is to find out if treatment with Aricept (donepezil) may improve some aspects of thinking abilities in patients with brain tumors who received radiation or chemotherapy. This research will also study whether persons having particular genes for a blood-borne substance called apolipoprotein E (APOE) are more likely to have thinking problems after radiation or chemotherapy treatment for their brain tumors. The findings of this study will help us find out whether Aricept can improve thinking abilities after cancer treatment, and whether some of the thinking difficulties may be in part related to having certain genes.

NCT ID: NCT00585572 Enrolling by invitation - Clinical trials for Mild Cognitive Impairment

Wisconsin Brain Donor Program

WBDP
Start date: March 2007
Phase:
Study type: Observational

The Wisconsin Brain Donor Program (WBDP) stores brain and other tissues/samples (e.g. blood and CSF) from deceased individuals who have participated in longitudinal research studies, as well as other select participants. These individuals have donated their tissues in order to aid scientific research. Through the collection of central and peripheral nervous tissues as well as (in select cases) skeletal muscle tissue, the WBDP strives to advance the knowledge of diseases of memory disorders, such as Alzheimer's Disease. Brain donations are needed from healthy individuals, as well as those affected by diseases of the nervous system.

NCT ID: NCT00570128 Completed - Down Syndrome Clinical Trials

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome

Start date: November 16, 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether donepezil HCl is effective and safe in improving cognitive dysfunction exhibited by children and adolescents with Down syndrome (DS). Effectiveness will be measured by rating communication, daily living skills, and social skills and relationships in subjects aged 10 to 17.

NCT ID: NCT00561678 Completed - Clinical trials for Postoperative Delirium

Perioperative Cognitive Function - Dexmedetomidine and Cognitive Reserve

Start date: February 2008
Phase: Phase 4
Study type: Interventional

Elderly patients who undergo anesthesia and non-cardiac surgery are subject to deterioration of brain function including the development of postoperative delirium (PD) and postoperative cognitive dysfunction (POCD). These disorders cause disability, distress for both patients and their families, are associated with other medical complications and account for significant additional health care costs. We currently use relatively primitive approaches to preventing and treating PD and POCD. Dexmedetomidine is a drug used for sedation in critically ill patients that provides some pain relief and controls the bodies response to stress. The sedation produced by dexmedetomidine appears more similar to natural sleep than any other drug used for anesthesia and postoperative sedation. Data suggesting that dexmedetomidine can prevent delirium following cardiac surgery and the developing understanding of the causes of PD and POCD suggest that dexmedetomidine will be particularly effective.

NCT ID: NCT00469482 Completed - Clinical trials for Cognitive Impairment

The SOMNUS Study: Sedative Optimization Via Monitoring Neurological Status

SOMNUS
Start date: June 2007
Phase: N/A
Study type: Interventional

A combined strategy of Richmond Agitation and Sedation Scale (RASS) clinical targeting plus bispectral index (BIS) guided sedation in mechanically ventilated, critically ill patients will decrease time on mechanical ventilation, decrease the duration of intensive care unit (ICU) delirium and coma, and will improve subacute neurocognitive function when compared to sedation guided by RASS targeting alone.

NCT ID: NCT00455143 Terminated - Clinical trials for Postoperative Delirium

Cognitive Protection - Dexmedetomidine and Cognitive Reserve

Start date: September 2006
Phase: Phase 4
Study type: Interventional

This is a pilot study to evaluate the effect of dexmedetomidine in the prevention of delirium in non-cardiac surgical patients. The preliminary data regarding the effect of dexmedetomidine on delirium comes from a study underway at Stanford. We propose to randomize fifty patients into two different protocols, one using dexmedetomidine until PACU discharge (hip replacement) and the other using dexmedetomidine for 24 hours in a monitored setting.

NCT ID: NCT00446485 Completed - Clinical trials for Mild Cognitive Impairment

Efficacy and Safety of Ginkgo Biloba Extract in Mild Cognitive Impairment and Cerebrovascular Insufficiency

Start date: May 2007
Phase: Phase 4
Study type: Interventional

The purpose of the study is to determine weather Ginkgo biloba standardized extract (24% ginkoflavonoglicozides and 6% terpenes) is effective in treatment of cognitive and concentration impairment